CC
STLN

Centiva Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Centiva Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$688K Buy
+224,245
New +$688K 0.01% 711
2021
Q2 		– Sell
-26,207
Closed -$261K – 1629
2021
Q1 		$261K Sell
26,207
-29,793
-53% -$317K 0.01% 859
2020
Q4 		$605K Buy
56,000
+6,000
+12% +$61.8K 0.02% 397
2020
Q3 		$518K Hold
50,000
– – 0.03% 327
2020
Q2 		$503K Buy
+50,000
New +$497K 0.03% 288

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centiva Capital's STLN Position: Q1 2026 in Review

Centiva Capital opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 224,245 shares worth $688K. The stake represents 0.01% of the portfolio and ranks #711 among its holdings. This is a return to the name: Centiva Capital previously reported a position in STLN as recently as Q1 2021.

Centiva Capital first reported a position in STLN in Q2 2020 and has held it in 5 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Centiva Capital held 224,245 shares of Starling Oncology Institute, Inc. Common Stock worth $688K as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Centiva Capital position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up 0.01% of Centiva Capital's portfolio in Q1 2026, its #711 holding.
  • Centiva Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and has held it in 5 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.